Phase 2 Study Supports Second-Line Axi-Cel in R/R LBCL - Targeted Oncology
Axicabtagene ciloleucel (axi-cel) shows promise as a second-line therapy for relapsed/refractory large B-cell lymphoma, with a 71% complete metabolic response at 3 months and manageable safety. The phase 2 study highlights its efficacy and safety, with ongoing evaluations of secondary endpoints and quality of life impacts.
Related Clinical Trials
Reference News
Phase 2 Study Supports Second-Line Axi-Cel in R/R LBCL - Targeted Oncology
Axicabtagene ciloleucel (axi-cel) shows promise as a second-line therapy for relapsed/refractory large B-cell lymphoma, with a 71% complete metabolic response at 3 months and manageable safety. The phase 2 study highlights its efficacy and safety, with ongoing evaluations of secondary endpoints and quality of life impacts.